ADC Therapeutics results after restructuring

 

• 3Q 2023 ZYNLONTA^®1 net sales of $14.3 million reflect disruption following restructuring of commercial organization, increased competition and higher gross-to-net deductions
• Operating expenses decreased 23%² year-over-yeardue to portfolio prioritization and operational efficiencies; Expected cash runway into mid-2025
• Prioritized pipeline progressing with initial data readouts from LOTIS-7 and studies of ADCT-601 targeting AXL and ADCT-901 targeting KAAG1 expected in 1H 2024
• Company to host conference call today at 8:30 a.m

Conference Call Details

ADC Therapeutics management will host a conference call and live audio webcast to discuss third quarter 2023 financial results and provide a company update today at 8:30 a.m. Eastern Time. To access the conference call, please register here. Registrants will receive the dial-in number and unique PIN. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under “Events & Presentations” in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.

https://www.biospace.com/article/releases/adc-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business-updates/